PMID- 12504827
OWN - NLM
STAT- MEDLINE
DCOM- 20030429
LR  - 20190513
IS  - 0008-6363 (Print)
IS  - 0008-6363 (Linking)
VI  - 57
IP  - 1
DP  - 2003 Jan
TI  - Effects of local MCP-1 protein therapy on the development of the collateral 
      circulation and atherosclerosis in Watanabe hyperlipidemic rabbits.
PG  - 178-85
AB  - OBJECTIVE: The objective of our study was to quantify the arteriogenic potency of 
      Monocyte Chemoattractant Protein-1 (MCP-1) under hyperlipidemic conditions. 
      Additionally, we aimed to determine the effects of locally applied MCP-1 on 
      systemic serum lipid levels as well as on atherosclerosis. METHODS: A total of 
      sixty-four Watanabe rabbits was treated with either low dose MCP-1 (1 
      microg/kg/week), high dose MCP-1 (3.3 microg/kg/week) or PBS as a control 
      substance. Substances were applied directly into the collateral circulation via 
      an osmotic minipump with the catheter placed in the proximal stump of the ligated 
      femoral artery. Either 1 week or 6 months after initiation of the treatment X-ray 
      angiography was performed as well as measurements of collateral conductance using 
      fluorescent microspheres. The extent of atherosclerosis was quantified in whole 
      aortas using Sudan IV staining. RESULTS: One week after ligation of the femoral 
      artery a significant increase in collateral conductance was observed in animals 
      treated with high dose MCP-1 (control: 2.2+/-0.8 ml/min/100 mmHg vs. MCP-1 high 
      dose: 8.9+/-2.0 ml/min/100 mmHg, P<0.05). Six months after femoral artery 
      ligation no differences were found between the treated and the control group 
      (PBS; 44.9+/-11.6 ml/min/100 mmHg, MCP-1; 47.8+/-11.5 ml/min/100 mmHg, P=NS). No 
      influence was found on serum lipids or on the development of atherosclerosis in 
      the present model. CONCLUSION: MCP-1 accelerates arteriogenesis upon femoral 
      artery ligation under hyperlipidemic conditions. Six months after treatment these 
      pro-arteriogenic effects of MCP-1 can no longer be observed. The present data do 
      not show an effect of local MCP-1 treatment on serum lipids or on 
      atherosclerosis. It should be noted however that a high standard deviation was 
      observed for the data on atherosclerotic surface area, necessitating additional 
      experiments in a different model of atherosclerosis.
FAU - van Royen, N
AU  - van Royen N
AD  - Department of Cardiology, University of Amsterdam, Amsterdam, The Netherlands. 
      vanroyen@med1.ukl.uni-freiburg.de
FAU - Hoefer, I
AU  - Hoefer I
FAU - Buschmann, I
AU  - Buschmann I
FAU - Kostin, S
AU  - Kostin S
FAU - Voskuil, M
AU  - Voskuil M
FAU - Bode, Ch
AU  - Bode Ch
FAU - Schaper, W
AU  - Schaper W
FAU - Piek, J J
AU  - Piek JJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Chemokine CCL2)
RN  - 0 (Lipids)
SB  - IM
MH  - Animals
MH  - Arteriosclerosis
MH  - Chemokine CCL2/*therapeutic use
MH  - *Collateral Circulation
MH  - *Femoral Artery/diagnostic imaging
MH  - Hyperlipidemias/blood/diagnostic imaging/*drug therapy
MH  - Ligation
MH  - Lipids/blood
MH  - Models, Animal
MH  - Rabbits
MH  - Radiography
EDAT- 2002/12/31 04:00
MHDA- 2003/04/30 05:00
CRDT- 2002/12/31 04:00
PHST- 2002/12/31 04:00 [pubmed]
PHST- 2003/04/30 05:00 [medline]
PHST- 2002/12/31 04:00 [entrez]
AID - S0008636302006156 [pii]
AID - 10.1016/s0008-6363(02)00615-6 [doi]
PST - ppublish
SO  - Cardiovasc Res. 2003 Jan;57(1):178-85. doi: 10.1016/s0008-6363(02)00615-6.